RIVANNA Builds Momentum With FDA-Cleared Imaging Platforms, AI Expansion, and New Growth Programs

RIVANNA continued to build momentum this week around its AI-enabled point-of-care imaging platforms, combining regulatory progress, conference visibility, and local recognition. The Charlottesville-based company focuses on clinical decision-support tools for neuraxial anesthesia and fracture care, as well as musculoskeletal ultrasound.

The company is leveraging recent U.S. Food and Drug Administration 510(k) clearance for its Accuro XV musculoskeletal ultrasound system, which has drawn coverage from trade outlets such as AuntMinnie.com, Diagnostic Imaging, ORTHOWORLD, Orthopedic Design & Technology, and ICE Magazine. Media reports highlight potential benefits for emergency department throughput and reduced reliance on radiography.

RIVANNA positions Accuro XV as a scalable platform intended to support multiple clinical applications rather than a single-use device. Early feasibility data indicating that non-physician operators can capture diagnostic-quality images after limited training supports a strategy aimed at task shifting and wider adoption in hospital and clinic settings.

In parallel, the company is advancing AI-enabled decision-support modules, including tools for enhanced bone visualization and automated fracture detection, which are described as progressing toward FDA clearance. RIVANNA emphasized its engagement with investors and industry partners at the North American MedTech World Awards, signaling a shift from pure development toward commercialization.

The company also plans a high-profile presence at DeviceTalks Boston on May 27–28, where co-founder and CEO Will Mauldin will present on the Accuro 3S platform, an FDA-cleared, AI-guided real-time neuraxial anesthesia system with an emphasis on obstetric use cases. The presentation is expected to focus on how AI-driven anatomical analysis can reduce procedural variability, lower training demands, and improve workflow and patient safety.

RIVANNA is preparing a Pioneer Partner program and a Trailblazer cohort of 25 sites as the next phase of Accuro 3S expansion, using a cohort-based rollout to gather data on clinical performance, user adoption, and potential revenue generation. Successful conversion of pilot sites to broader institutional use could provide early commercial validation and reinforce the company’s position in AI-guided procedural imaging.

Regionally, RIVANNA was nominated for Innovator of the Year at the 2026 Charlottesville Business Innovation Council Annual Awards Gala, underscoring its integration into the local innovation ecosystem. The recognition may support future talent attraction, partnerships, and access to regional capital and grants, complementing the company’s broader market-facing initiatives.

Overall, the week’s developments portray RIVANNA as consolidating regulatory wins, expanding visibility among clinicians and investors, and launching structured expansion programs for its AI-guided platforms, developments that could materially influence its trajectory in point-of-care imaging and clinical decision support over time.